W. L. Gore & Associates (Gore) today announced that the GORE® Hybrid Vascular Graft was awarded Gold Winner in the Implant and Tissue-Replacement Products category of the 2012 Medical Design Excellence Awards (MDEA) competition. The Gore Device is an expanded polytetrafluoroethylene (ePTFE) vascular prosthesis that provides a streamlined solution for challenging dialysis access, aortic debranching, and arterial bypass procedures. The award-winning prosthesis provides a new way in for better outflow and the potential to significantly improve patient outcomes.
MAQUET Cardiopulmonary, a business unit of MAQUET Cardiovascular and a leader in extracorporeal life support (ECLS) systems, today announced that they have signed an agreement with Avalon Laboratories to acquire its Avalon Elite® Bi-Caval Dual Lumen Catheter and complimentary vascular access kits for use during ECLS.
Twelve-month results from the BIOSOLVE-I study with the DRug Eluting Absorbable Metal Scaffold (DREAMS) demonstrate safety and confirm vessel vasomotion. T he results from the BIOSOLVE-I study were presented at the European Course on Revascularization in Paris (EuroPCR) by Professor Michael Haude, Lukaskrankenhaus, Neuss, Germany.
The first-in-man experience results with a new bioresorbable scaffold for superficial femoral artery lesions were presented by Andrew Holden, Auckland, New Zealand, yesterday. Holden described the Stanza Bioresorbable Scaffold System from 480 Biomedical and initial case experience from the first patients treated in the STANCE trial.
Five-year data from the THU"DER trial demonstrated a 59% relative reduction in target lesion revascularisation rates in popliteal arteries of patients with peripheral arterial disease (PAD) treated with the Cotavance drug-eluting balloon (Medrad) with Paccocath technology compared to standard balloon angioplasty. Additionally, for patients requiring target lesion revascularisation, the average time to revascularisation before target lesion revascularisation was extended by 448 days in patients treated with the Cotavance catheter.
Initial data from the IN.PACT Global study, presented at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference (Washington, DC, USA) show a clinically-driven target lesion revascularisation rate of 8.7% at 12 months for the first 655 patients enrolled in the study. According to Medtronic, the data validate the findings from the IN.PACT SFA trial.
En los adultos sanos que toman una aspirina de baja dosis todos los días no aumenta el riesgo de padecer hematuria microscópica, según revela un estudio de Corea.
[+]
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos